Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The beta-globin gene locus, located on chromosome 11p15.4, is a cluster of genes including HBB, which encodes the beta-subunit of adult hemoglobin (HbA) (NIH, 2023). In autologous CD34+ hematopoietic stem cells, this locus serves as a primary target for gene therapy to treat hereditary hemoglobinopathies like beta-thalassemia and sickle cell disease (PubMed, 2022). Current therapeutic interventions, such as betibeglogene autotemcel, utilize lentiviral vectors to insert a functional HBB gene into the patient's own stem cells ex vivo (FDA, 2022). These modified cells are then re-infused, where they produce functional hemoglobin, potentially eliminating the need for lifelong blood transfusions (StatPearls, 2023). Safety considerations for targeting this locus include the risk of insertional mutagenesis and the toxicities associated with the required myeloablative conditioning (PubMed, 2021).
Lentiviral vector-mediated gene addition of a functional beta-globin gene into autologous hematopoietic stem cells to restore production of adult hemoglobin.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-globin gene locus (HBB locus).